FGFR2 and neoplasm: mAbs can also be conjugated to cytotoxic agents, as seen in BAY 1187982, a combination of BAY 1179470 and auristatin, which demonstrated potent anti-tumor activity in FGFR2-positive advanced cancers by specifically delivering toxicity to FGFR2-expressing cells [122].